Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3933-3121
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1 million
Profitability
Miscellaneous
Employees10
Next Earnings DateN/A
OptionableNot Optionable
KITOV PHARMA LT/S (NASDAQ:KTOV) Frequently Asked Questions
What is KITOV PHARMA LT/S's stock symbol?
KITOV PHARMA LT/S trades on the NASDAQ under the ticker symbol "KTOV."
Has KITOV PHARMA LT/S been receiving favorable news coverage?
Press coverage about KTOV stock has been trending very negative on Wednesday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. KITOV PHARMA LT/S earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the near future. View News Stories for KITOV PHARMA LT/S.
Who are some of KITOV PHARMA LT/S's key competitors?
Some companies that are related to KITOV PHARMA LT/S include VERONA PHARMA P/S (VRNA), Merrimack Pharmaceuticals (MACK), Pharmaxis (PXSLY), Eyenovia (EYEN), Alpine Immune Sciences (ALPN), Oramed Pharmaceuticals (ORMP), ASLAN PHARMACEU/ADR (ASLN), SUMMIT THERAPEU/S (SMMT), Arbutus Biopharma (ABUS), Melinta Therapeutics (MLNT), Spring Bank Pharmaceuticals (SBPH), Aridis Pharmaceuticals (ARDS), Agile Therapeutics (AGRX), Tiziana Life Sciences (TLSA) and ESSA Pharma (EPIX).
What other stocks do shareholders of KITOV PHARMA LT/S own?
Who are KITOV PHARMA LT/S's key executives?
KITOV PHARMA LT/S's management team includes the folowing people:
- Dr. John Paul Waymack, Founder, Chairman & Chief Medical Officer (Age 67)
- Mr. Isaac Israel, CEO & Director (Age 41)
- Dr. Hadas Reuveni, Founder & CTO of TyrNovo (Age 52)
- Mr. Simcha Rock CPA, M.B.A., CPA, MBA, Strategic Advisor & Director (Age 69)
- Dr. Gil Ben-Menachem M.B.A., MSc, MBA, Ph.D., VP of Bus. Devel. & Director (Age 52)
When did KITOV PHARMA LT/S IPO?
(KTOV) raised $13 million in an IPO on Friday, November 20th 2015. The company issued 3,200,000 shares at a price of $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar served as the underwriters for the IPO.
How do I buy shares of KITOV PHARMA LT/S?
Shares of KTOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is KITOV PHARMA LT/S's stock price today?
One share of KTOV stock can currently be purchased for approximately $0.72.
How big of a company is KITOV PHARMA LT/S?
KITOV PHARMA LT/S has a market capitalization of $14.06 million and generates $1 million in revenue each year. The company earns $-5,200,000.00 in net income (profit) each year or $0.39 on an earnings per share basis. KITOV PHARMA LT/S employs 10 workers across the globe.View Additional Information About KITOV PHARMA LT/S.
What is KITOV PHARMA LT/S's official website?
How can I contact KITOV PHARMA LT/S?
KITOV PHARMA LT/S's mailing address is One Azrieli Center Round Tower 132 Menachem Begin Road, Tel Aviv L3, 6701101. The company can be reached via phone at 972-3933-3121 or via email at [email protected]
MarketBeat Community Rating for KITOV PHARMA LT/S (NASDAQ KTOV)
MarketBeat's community ratings are surveys of what our community members think about KITOV PHARMA LT/S and other stocks. Vote "Outperform" if you believe KTOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KTOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
